Sensitivities of Human Glioma Cell Lines to Interferons and Double-stranded RNAs Individually and in Synergistic Combinations

Overview

Journal J Neurooncol

Publisher Springer

Date 1987 Jan 1

PMID 2450181

Citations 7

Authors

R S Dick

H R Hubbell

Affiliations

Soon will be listed here.

Abstract

The antiproliferative effects of human interferons (IFNs) and double-stranded RNAs (dsRNAs) were studied in five human glioma cell lines. Dose response curves were generated over a 72 hour treatment period. The concentration of interferon or double-stranded RNA necessary to produce a 50% antiproliferative response (GI50) was calculated by linear regression analysis. Two cell lines were more sensitive to IFN-beta than to IFN-alpha, one cell line was more sensitive to IFN-alpha than to IFN-beta and two cell lines had approximately equal sensitivities to both interferons. All cell lines showed some sensitivity to either IFN-alpha or IFN-beta. IFN-gamma had no antiproliferative effect on any of the cell lines. In addition, only one of the cell lines displayed sensitivity to dsRNA, in which the response to poly(I).poly(C) was greater than that to a mismatched analogue of poly(I).poly(C), r(I)n.r(C12,U)n (Ampligen). There was no correlation between the sensitivities to type I IFNs (alpha and beta), type II IFN (gamma) or the dsRNAs. The antiproliferative effect of combinations of IFNs, or IFNs and Ampligen, was studied in one of the cell lines. A significant synergistic antitumor effect was seen with all of the IFN/Ampligen combinations (p less than 0.02), including IFN-gamma/Ampligen, even though these cells were resistant to IFN-gamma alone. Synergy was also seen in the IFN-alpha/IFN-gamma (p less than 0.02) and IFN-beta/IFN-gamma (p less than 0.05) combinations. The IFN-alpha/IFN-beta combination gave an additive antitumor effect. These results indicate that IFN-alpha and IFN-beta alone or combinations of type I IFNs, type II IFNs and Ampligen can be effective in inhibiting the growth of glioma cells.

Citing Articles

Discovery and Use of Long dsRNA Mediated RNA Interference to Stimulate Antiviral Protection in Interferon Competent Mammalian Cells.

Semple S, Au S, Jacob R, Mossman K, DeWitte-Orr S Front Immunol. 2022; 13:859749.

PMID: 35603190 PMC: 9120774. DOI: 10.3389/fimmu.2022.859749.

A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy.

De Waele J, Verhezen T, van der Heijden S, Berneman Z, Peeters M, Lardon F J Exp Clin Cancer Res. 2021; 40(1):213.

PMID: 34172082 PMC: 8229304. DOI: 10.1186/s13046-021-02017-2.

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).

Butowski N, Chang S, Junck L, DeAngelis L, Abrey L, Fink K J Neurooncol. 2008; 91(2):175-82.

PMID: 18797818 PMC: 4779120. DOI: 10.1007/s11060-008-9693-3.

Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3.

Levy D, Lew D, Decker T, Kessler D, Darnell Jr J EMBO J. 1990; 9(4):1105-11.

PMID: 2108862 PMC: 551785. DOI: 10.1002/j.1460-2075.1990.tb08216.x.

Cyclic AMP mediates the direct antiproliferative action of mismatched double-stranded RNA.

Hubbell H, Boyer J, Roane P, Burch R Proc Natl Acad Sci U S A. 1991; 88(3):906-10.

PMID: 1846967 PMC: 50923. DOI: 10.1073/pnas.88.3.906.

References

BRADLEY N, Darling J, Oktar N, BLOOM H, Thomas D, Davies A . The failure of human leukocyte interferon to influence the growth of human glioma cell populations: in vitro and in vivo studies. Br J Cancer. 1983; 48(6):819-25. PMC: 2011555. DOI: 10.1038/bjc.1983.272. View

Kohno M, IDA N, Nagao S, Tanaka N, Sekiguchi F, Uenishi N . Effects of human fibroblast interferon on human tumors transplanted into nude mice: sensitivity of human tumors to interferon. Gan. 1982; 73(6):945-51. View

Hubbell H, Liu R, Maxwell B . Independent sensitivity of human tumor cell lines to interferon and double-stranded RNA. Cancer Res. 1984; 44(8):3252-7. View

Nakamura O, Shitara N, Matsutani M, Takakura K, Machida H . Phase I-II trials of poly(ICLC) in malignant brain tumor patients. J Interferon Res. 1982; 2(1):1-4. DOI: 10.1089/jir.1982.2.1. View

Czarniecki C, Fennie C, Powers D, Estell D . Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons. J Virol. 1984; 49(2):490-6. PMC: 255490. DOI: 10.1128/JVI.49.2.490-496.1984. View

Nakagawa Y, Hirakawa K, Ueda S, Suzuki K, Fukuma S, Kishida T . Local administration of interferon for malignant brain tumors. Cancer Treat Rep. 1983; 67(9):833-5. View

Hubbell H, CARTER W, Strayer D . Antiproliferative and immunomodulatory actions of beta-interferon and double-stranded RNA, individually and in combination, on human bladder tumor xenografts in nude mice. Cancer Res. 1985; 45(6):2481-6. View

BERENBAUM M . Criteria for analyzing interactions between biologically active agents. Adv Cancer Res. 1981; 35:269-335. DOI: 10.1016/s0065-230x(08)60912-4. View

Lin S, GREENE J, Tso P, CARTER W . Sensitivity and resistance of human tumor cells to interferon and rIn . rCn. Nature. 1982; 297(5865):417-9. DOI: 10.1038/297417a0. View

10.

De Clercq E, GEORGIADES J, Edy V, SOBIS H . Effect of human and mouse interferon and of polyriboinosinic acid.polyribocytidylic acid on the growth of human fibrosarcoma and melanoma tumors in nude mice. Eur J Cancer (1965). 1978; 14(11):1273-82. DOI: 10.1016/0014-2964(78)90235-9. View

11.

Brodsky I, Strayer D, Krueger L, CARTER W . Clinical studies with ampligen (mismatched double-stranded RNA). J Biol Response Mod. 1985; 4(6):669-75. View

12.

Strayer D, Weisband J, CARTER W, Black P, Nidzgorski F, Cook A . Growth of astrocytomas in the human tumor clonogenic assay and sensitivity to mismatched dsRNA and interferons. Am J Clin Oncol. 1987; 10(4):281-4. DOI: 10.1097/00000421-198708000-00003. View

13.

Rashidbaigi A, Kung H, Pestka S . Characterization of receptors for immune interferon in U937 cells with 32P-labeled human recombinant immune interferon. J Biol Chem. 1985; 260(14):8514-9. View

14.

Taylor-Papadimitriou J, Balkwill F . Implications for clinical application of new developments in interferon research. Biochim Biophys Acta. 1982; 695(1):49-67. DOI: 10.1016/0304-419x(82)90006-3. View

15.

Fisher P, Grant S . Effects of interferon on differentiation of normal and tumor cells. Pharmacol Ther. 1985; 27(2):143-66. DOI: 10.1016/0163-7258(85)90067-1. View

16.

Fleischmann Jr W, Kleyn K, Baron S . Potentiation of antitumor effect of virus-induced interferon by mouse immune interferon preparations. J Natl Cancer Inst. 1980; 65(5):963-6. View

17.

Bogdahn U, Fleischer B, Hilfenhaus J, Rothig H, Krauseneck P, MERTENS H . Interferon-beta in patients with low-grade astrocytomas--a phase I study. J Neurooncol. 1985; 3(2):125-30. DOI: 10.1007/BF02228888. View

18.

Freeman A, OMalley J, Stutzman L, Bjornsson S, CARTER W . Pharmacologic effects of polyinosinic-polycytidylic acid in man. J Med Virol. 1977; 1(2):79-93. DOI: 10.1002/jmv.1890010202. View

19.

Robinson R, DEVITA V, Levy H, Baron S, Hubbard S, Levine A . A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst. 1976; 57(3):599-602. DOI: 10.1093/jnci/57.3.599. View

20.

Hubbell H, Craft J, Leibowitz P, Gillespie D . Synergistic antiproliferative effect of recombinant alpha-interferons with recombinant gamma-interferon. J Biol Response Mod. 1987; 6(2):141-53. View